Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? by W. David Strain & Christine Smith
REVIEW
Cardiovascular Outcome Studies in Diabetes: How Do
We Make Sense of These New Data?
W. David Strain . Christine Smith
Received: January 18, 2016 / Published online: March 24, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Poorly controlled diabetes is characterized by
premature cardiovascular mortality and
morbidity. The mechanisms linking
hyperglycemia with accelerated atherosclerotic
disease have not been fully elucidated; however,
are thought to be mediated through vascular
inflammation, oxidative stress and endothelial
dysfunction. The advent of incretin-based
therapy, whether by increasing endogenous
glucagon-like peptide (GLP)-1 and
glucose-dependent inhibitory polypeptide by
inhibition of their breakdown using di-peptidyl
peptidase 4 inhibitors, or augmenting GLP-1
activity using either exendin-4-based drugs or
synthetic GLP-1 analogs promised not just
improvements in glycemic control, but
improvements in endothelial function, lipid
profiles and markers of vascular inflammation.
As such, it was anticipated they would
demonstrate cardiovascular benefit in those
with diabetes, indeed early meta-analyses
suggested cardiovascular events would be
reduced. To date, however, this benefit has
failed to materialize, indeed the cardiovascular
outcome trials, whilst meeting their primary
endpoint of cardiovascular safety, have failed to
demonstrate any improvements in stroke or
myocardial infarction. This review will explore
the data and attempt to answer the question:
what went wrong?
Keywords: Cardiovascular outcomes; DPP-4
inhibition; Endothelial function; GLP-1
receptor agonists; Incretin
INTRODUCTION
Diabetes mellitus currently affects
approximately 415 million people worldwide
[1]. It is estimated the global health expenditure
on diabetes is approximately $673billion; indeed
in the USA alone the cost is approximately $320
billion. Of this cost, however, only 12% is spent
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on directlymanaging the diabetes itself, with the
majority of the expenditure being on the
complications of the disease [2]. Cardiovascular
disease is the most common cause of death and
disability among people with diabetes; the
diagnosis conferring a twofold excess risk of
cardiovascular disease, independent of the
usually accompanying adverse lipid and weight
profile [3]. Therefore, reducing the
cardiovascular risk of people with diabetes has
beenat the forefrontof diabetes researchwith the
intention of improving the health andwellbeing
of the population whilst simultaneously
reducing the global financial burden of the
disease. At the core of cardiovascular
protection, good blood pressure control, weight
reduction, improved physical activity and
appropriate statin usage have been
demonstrated to substantially reduce event rate
[4].
Diabetes is diagnosed and characterized by
hyperglycemia, and thus for many years, strict
glycemic control was thought to be key to
improving cardiovascular events. Whereas tight
glycemic control unequivocally improves
microvascular outcomes, the benefit has not
been consistently demonstrated in the
macrovasculature [5–7]. Multiple explanations
have been presented for this lack of benefit, or
in the case of the ACCORD study
(ClinicalTrials.gov identifier, NCT00000620)
the apparent harm [6]. There is still no
unifying accepted theory. Many have
suggested the predominantly insulinocentric
approach to the management of glucose may
have contributed to the lack of benefit [8] as
these therapies are associated with significant
weight gain [9] and risk of hypoglycemia [10].
Although unlikely to account for the complete
lack of benefit seen in these studies it is
generally accepted that these recognized
complications of treatment mitigate the
benefit of good glycemic control. Indeed, the
2.7-fold excess cardiovascular mortality
reported in the systematic review and
meta-analysis of observational studies was in
part attributed to these complications of
treatment [11]. As such, it was hoped the
advent of incretin-based therapies, designed to
support physiological regulation of glycemia
without precipitating hypoglycemia or weight
gain, would provide an alternative treatment
strategy with cardioprotective benefits. Early
phase 2 and 3 studies provided promising
results, however, as yet, these benefits have
failed to be demonstrated.
This review will explore the pre-clinical and
early clinical data and compare it with the
subsequent larger clinical trials to propose
potential explanations for the disconnect
between the physiological benefits presented
in early work and the lack of apparent benefit
demonstrated in large-scale cardiovascular
safety studies.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
THE INCRETIN SYSTEM IN HEALTH
AND DISEASE
The pathophysiology of diabetes includes
attenuated pancreatic a and b cell function
resulting in inappropriate glucagon release and
diminished insulin production, cellular insulin
resistance in the muscles, liver, brain and
adipose tissues, increased renal glucose
reabsorption and impairments of the incretin
system [12]. Incretins are peptides secreted from
the gut in response to ingestion of food. The
two peptides, glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like
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polypeptide 1 (GLP-1) account for as much as
90% of the ‘‘incretin effect’’ first described by
Jean LaBarre in 1930 [13]. They are responsible
for as much as half of the glucose-dependent
insulin release after food ingestion in addition
to suppressing glucagon release. Further, in
health they have been attributed with several
preparatory responses to nutrition, including
suppressing hepatic gluconeogenesis,
promoting satiety and inhibiting gastric
emptying. People with diabetes have reduced
incretin production and enhanced degradation
by the enzyme di-peptidyl peptidase-4 (DPP-4)
[14]. Research into these pathophysiological
deficits has resulted in the successful
development and use of therapies either
increasing endogenous GLP-1 by inhibiting its
breakdown by DPP-4 or administering synthetic
GLP-1 receptor agonists. The latter class of drugs
is further subdivided into agents based on
exendin-4, originally isolated from the Gila
monster of the Southwestern United States,
which has approximately 50–53% homology
with human native GLP-1 making it resistant to
DPP-4 degradation, but interacts with the GLP-1
receptor, or the synthetic GLP-1 analogs which
share up to 97% homology with endogenous
GLP-1, but have been engineered to resist DPP-4
breakdown. These agents stimulate appropriate
insulin secretion, suppress inappropriate
glucagon release and thus regulate glucose
with a low risk of hypoglycemia. There is
substantial interest, however, in the
non-glycemic effects these agents had.
CARDIOVASCULAR EFFECTS
OF INCRETIN-BASED THERAPY
In vitro studies exploring the effect of GLP-1
on endothelial function demonstrate that
there are vascular benefits which are not
mediated through improvements in
hyperglycemia, weight loss or the
accompanying blood pressure reduction.
Exendin-4 stimulates proliferation of
endothelial cells, a critical step in endothelial
repair, arterial healing, and angiogenesis, by a
GLP-1 receptor-dependent mechanism [15].
The endothelial dysfunction that characterizes
premature atherosclerosis is attenuated in
human umbilical vein endothelial cells
(HUVECs) exposed to the GLP-1 analog
liraglutide similarly through GLP-1
receptor-dependent mechanisms [16].
Liraglutide also shows marked anti-oxidative,
anti-inflammatory, and anti-apoptotic effects
on HUVECs exposed to tumor necrosis factor
alpha (TNFa) [17], and attenuates the
accompanying endothelial cell dysfunction
[18]. Additionally, liraglutide reduced
hyperglycemia-induced endoplasmic reticulum
stress in HUVECs via mitochondrial fusion
processes, thereby reducing apoptosis [19].
Interestingly this effect may be a direct
mitochondrial effect rather than a GLP-1
receptor-mediated effect. Exenatide, however,
failed to protect rat femoral arterial ring
endothelial cells from triglyceride-induced
cellular dysfunction [20].
In the animal models GLP-1 also appears to
have favorable effects on vascular function,
independent of its glucose lowering effects.
GLP-1 administration mediates
endothelial-dependent relaxation in the rat
pulmonary artery [21, 22], which was attenuated
in the presence of a nitric oxide synthase
antagonist suggesting the involvement of nitric
oxide (NO) inmediating its vascular effects. This is
supported by observations that GLP-1 promotes
NO-dependent relaxation of mouse mesenteric
arteries [23]. The GLP-1 vascular effect appears to
vary by vascular bed, causing
endothelial-independent relaxation, via the
GLP-1 receptor, in femoral arteries [24] but
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having no impact on rat aorta isolates [21]. GLP-1
is also protective against ischemia–reperfusion
injury in isolated rat hearts [23, 25–28] and has
renoprotective (reducing proteinuria and
microalbuminuria) effects, in addition to the
cardioprotective effects in Dahl salt-sensitive
hypertensive rats [29]. Whether these effects are
mediated directly via the GLP-1 receptor is
unclear, as the vasodilatory effects have been
observed to be both dependent [24] and
independent [23] of the GLP-1 receptor. In the
latter of these studies, GLP-1(9-36), which is the
product from the degradation of GLP-1 by DPP-4,
mediated relaxation of mouse mesenteric arteries
[23]. Thus, it is clearly evident that GLP-1 acts as a
vasodilator in animal models potentially having
cardioprotective properties, although whether
this is dependent on GLP-1 receptor or another
mechanism remains to be elucidated.
Early work in humans replicated these
findings. Acute administration of GLP-1
increased flow-mediated dilatation
(endothelial dependent) in type 2 diabetic
male subjects with coronary artery disease but
had no significant effect on young healthy, lean
male subjects in whom no existing failure of
endogenous GLP-1 activity would be
anticipated [30]. In a broader general
population sample aged 18–50 years, GLP-1
did improve forearm blood flow by
approximately 30% and augmented
endothelial-dependent forearm blood flow
response to acetylcholine by up to 40% [31].
Conversely, endothelial-independent function
was not influenced by the acute administration
of GLP-1 in either diabetic or healthy
individuals suggesting GLP-1 improves
function rather than structure [30, 31]. GLP-1
infusions were also shown to improve regional
and global left ventricular function when
administered within 6 h of an acute
myocardial infarction and improve systolic
function after successful primary angioplasty
in those with severe left ventricular dysfunction
[32].
Observations from early clinical trials
suggested these benefits would extend into
improvements in cardiovascular outcomes. A
meta-analysis of the GLP-1 receptor agonist use
demonstrated a reduction in blood pressure of
3.6/1.4 mmHg, weight of 2.9 kg and total
cholesterol of 0.1 mmol/L [33]. A
retrospective analysis of obese people with
type 2 diabetes suggested an improvement in
both blood pressure and C-reactive protein
with the exendin-4-based GLP-1 Receptor
agonist, exenatide [34]. A meta-analysis of the
prospective liraglutide effect and action in
diabetes (LEAD) studies, the registration
program for the GLP-1 analog, liraglutide,
demonstrated improvements in lipid profile,
B-type natriuretic peptide, high-sensitivity
C-reactive protein and plasminogen activator
inhibitor-1 all of which have been associated
with cardiovascular outcomes [35]. These
benefits have also been demonstrated with
exenatide and the DPP-4 inhibitor sitagliptin,
suggesting this is a class effect [36, 37].
Reductions in postprandial triglycerides and
apoB48, again both tightly associated with
cardiovascular risk, have been demonstrated
with both the DPP-4 inhibitor, vildagliptin
[38], and the GLP-1 analog, liraglutide [39].
CARDIOVASCULAR OUTCOME
DATA
During pre-clinical investigation of incretin
therapies, most trials record and adjudicate
cardiovascular events. Although differing in
protocols, the standardized recording and
reporting of major adverse cardiac events
(MACE) allows for meaningful meta-analyses.
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In a meta-analysis of 25 trials lasting[6 months
and reporting at least one cardiovascular event,
GLP-1 receptor agonists demonstrated a
significant 49% reduction in MACE (p\0.03)
compared to placebo and a trend towards a 22%
improvement versus active comparator. This
failed to reach statistical significance due to the
small numbers of events, short-term nature of
the studies and the low-risk nature of the
participants [40]. A similar benefit was seen in
DPP-4 inhibitor trials, although with 70 trials to
analyze, the 29% reduction in MACE was highly
significant [41]. Again this analysis was limited
by the relatively short duration of the studies
and the relatively pure and healthy populations
that were studied in these regulatory trials.
Since the concern over rosiglitazone
potentially increasing cardiovascular events
(subsequently refuted), licensing with the Food
and Drug Administration (FDA), however,
requires a priori cardiovascular outcome trials
(CVOTs) to demonstrate cardiovascular safety
in anti-glycemic agents. As such there are
currently in excess of 100,000 people with
diabetes worldwide participating in CVOTs
using incretin-based therapies. To date, four of
the trials have reported the trial to evaluate
cardiovascular outcomes after treatment with
sitagliptin (TECOS, ClinicalTrials.gov identifier,
NCT00790205) [42], saxagliptin and
cardiovascular outcomes in patients with type
2 diabetes (SAVOR-TIMI 53, ClinicalTrials.gov
identifier, NCT01107886) [43] and the
examination of cardiovascular outcomes with
alogliptin versus standard of care (EXAMINE
ClinicalTrials.gov identifier, NCT00968708)
[44], using DPP-4 inhibitors, and the
evaluation of lixisenatide in acute coronary
syndrome (ELIXA, ClinicalTrials.gov identifier,
NCT01147250) using lixisenatide. Whilst
meeting all of the safety requirements of the
FDA, many have felt disappointment regarding
the lack of benefit achieved in these trials. The
TECOS study randomized 14,671 people with
diabetes and established cardiovascular disease
to receive sitagliptin or placebo. After a median
of 3.0 years, there was no difference in the
composite of cardiovascular outcome namely
cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke, or hospitalization
for unstable angina, with a hazard ratio (HR) of
0.98 (95% confidence interval [CI] 0.88–1.09).
The EXAMINE study explored the effect of
alogliptin in people with type 2 diabetes
post-myocardial infarction or acute coronary
syndrome for a median of 18 months and
demonstrated a similar HR of 0.96 (95% upper
limit of confidence interval 1.16) compared to
placebo. SAVOR-TIMI demonstrated an HR of
exactly 1.0 (95% CI 0.89–1.12) when comparing
saxagliptin with placebo in 16,492 people at risk
of or with a history of cardiovascular events for
a median 2.1 years. The ELIXA study differed
from the DPP-4-based studies, in that it was
originally designed to demonstrate the
superiority of the exendin-4-based GLP-1
receptor agonist, lixisenatide, over placebo
after acute coronary syndrome. The 6068
participants recruited after acute coronary
syndromes took either lixisenatide or placebo
for a median of 25 months. Again, there was no
difference in cardiovascular events (HR 1.02,
95% CI 0.89–1.17) although this still met the
FDA’s requirements for demonstrating
cardiovascular safety.
Of these studies, the result that generated
most attention was the post hoc analysis of the
non-adjudicated outcome for admissions due to
heart failure in the SAVOR-TIMI study. In the
first 6 months of the study there was an increase
of 0.7% in hospitalization due to heart failure,
which amounted to a 27% relative risk increase
[45]. Despite the fact these were
non-adjudicated outcomes in patients with
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pre-existing heart failure, the highly significant
increase in events raised considerable concerns.
As a result, existing studies were required to
perform an analysis of heart failure admissions.
The EXAMINE study showed a similar trend of
19% increase in admissions, although due to
small numbers this did not reach significance
[46]. TECOS, reassuringly, showed no increase
in heart failure signal with an HR of 1.0 (95% CI
0.83–1.20). There are several potential reasons
that have been hypothesized for this. The first
simply suggests that the treatment of
hyperglycemia reduces the osmotic diuresis
effect of glucose, thereby increasing the
symptoms of pre-existing heart failure. Others
have hypothesized that this is simple statistical
chance, although the similar trend in EXAMINE
would appear to refute this. Other potential
mechanisms include the potential for drug
interactions, notably with
angiotensin-converting enzyme
(ACE)-inhibitors or diuretics, which are more
likely with saxagliptin which does interact with
the CYP3A4/A5 inhibitors of the cytochrome
p450 pathway. This, however, does not account
for the trend seen with alogliptin. An
alternative explanation is found in the other
metabolites of DPP-4; B-type natriuretic peptide
(BNP), neuropeptide Y (NPY), peptide YY (PYY),
substance P and stromal cell-derived factor 1
alpha (SDF-1a) [47]. These are all cardioactive
substrates that influence vascular function. In
isolation and in animal models increasing these
by inhibition of DPP-4 should result in
improved function; however, it is unknown
whether interaction between and the relative
balance of such factors paradoxically diminish
function. Further, long-term DPP-4 inhibition
may upregulate alternative compensatory
degradation mechanisms, such as neutral
endopeptidases. This is analogous to the
increased chymase activity in long-term
ACE-inhibitor use that sees angiotensin 2
levels rise to pre-treatment levels within
12 months. Neutral endopeptidases
preferentially degrade BNP, thereby reducing
the cardioprotective natriuretic effect in those
with heart failure. The neutral effect of
sitagliptin in TECOS, however, despite similar
populations makes the latter explanation less
likely.
WHAT CAUSES THE DISCONNECT
BETWEEN THE EARLY CLINICAL
WORK AND THE RANDOMIZED
CONTROLLED TRIALS?
There has been much deliberation as to why the
potential benefit promised in thepre-clinical and
early clinical work has not been realized in the
definitive randomized controlled trials. One
hypothesis explores the possibility that this
may be simply due to the duration of the
studies. Indeed, if the heart protection study
(HPS) or the Scandinavian simvastatin survival
study (4S) had been censored at 18 months or
2 years they would have not demonstrated any
benefit from simvastatin [48, 49], yet statin
therapy is widely accepted as a core element of
cardiovascular risk reduction. If this is the case,
studies such as the liraglutide effect and action in
diabetes: evaluation of cardiovascular outcome
results (LEADER, ClinicalTrials.gov identifier,
NCT01179048) [50] and the cardiovascular
outcome trial of linagliptin versus glimepiride
in type 2diabetes (CAROLINA,ClinicalTrials.gov
identifier, NCT01243424) [51] trials that have a
study minimum duration of 3.5 years (the point
at which the HPS curves were clearly diverged)
should show benefit. The reduction in
cardiovascular events suggested by the early
meta-analyses, however, was present in studies
with a mean duration of 44.1 weeks [41]. Thus,
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duration of exposure to agents may not be the
only factor.
Another significant difference between the
regulatory studies that contributed to the
meta-analyses and the subsequent
cardiovascular outcome trials is the duration
of diabetes in those studied. Regulatory studies
tend to be performed in otherwise well
participants, early in diabetes. Complex
multi-morbid patients, such as those enrolled
in TECOS, EXAMINE, SAVOR-TIMI and ELIXA
are rarely used in these studies to minimize
inter-participant variability and maximize the
ability to detect differences. Event driven
cardiovascular outcome trials, however, prefer
high-risk patients to maximize the event rate
and increase study power. This necessitates a
longer duration of diabetes and multi-morbidity
driven polypharmacy.
To date, the only trial to demonstrate
cardiovascular benefit from glycemic control is
the UKPDS (ClinicalTrials.gov identifier,
NCT01099865) [5], which took newly
diagnosed people with diabetes. The
subsequent glycemic control trials, ACCORD,
ADVANCE (ClinicalTrials.gov number,
NCT00145925) and VADT (ClinicalTrials.gov
identifier, NCT00032487) failed to demonstrate
benefit [6, 7, 52, 53]. The failure to achieve
benefit in these studies has been attributed to
existing bad legacy effect from the preceding
8–12 years of poor glycemic control. Until
recently it was felt that this legacy effect was
purely an incremental accumulation of vascular
damage, rather than an ongoing process. Recent
work has demonstrated early adverse glycemic
exposure triggers acute changes in protein
expression, notably p66SHC in the
mitochondria. This adaptor protein functions
as a redox enzyme within the mitochondria
responsible for reactive oxygen species
generation and subsequent cellular apoptosis,
vascular inflammation and endothelial
dysfunction [54]. Gene silencing of p66SHC
blunts persistent endothelial dysfunction and
oxidative stress in the vasculature of diabetic
mice [55]. Elsewhere, hyperglycemia has been
demonstrated to trigger epigenetic changes.
Deacetylation of the SIRT-1 gene and tumor
suppressor p53 occurs [56]. These have both been
demonstrated to control p66SHC transcription
[57, 58]. Thus, the epigenetic changes in the
SIRT-1 and p53 genes may perpetuate the
original hyperglycemic effects. Interestingly
metformin has been demonstrated to reverse
the effects of SIRT-1 [59], in keeping with the
observed benefit in UKPDS whereby metformin
was substantially superior to sulphonylurea and
insulin-based therapy [60]. If the failure of
benefit in the existing trials is attributable to
this, the vildagliptin efficacy in combination
with metformin for early treatment of type 2
diabetes (VERIFY, ClinicalTrials.gov identifier,
NCT01528254),which is takingnewlydiagnosed
people with diabetes and randomizing them to
receive either immediate DPP-4 combination
with metformin or metformin alone, may
demonstrate a benefit. Unfortunately, the
primary endpoint of this study; time to initial
treatment failure rate and rate of loss in glycemic
control over time, may result in the study being
terminated before being able to demonstrate a
cardiovascular benefit.
Finally, these complex multi-morbid
patients are characterized by polypharmacy,
whereas regulatory trials are usually performed
with as few concomitant prescriptions as
possible. It is known that glibenclamide, and
to a lesser extent glimepiride, attenuates the
vascular benefit of GLP-1 [31]. This is most
likely mediated through effects on
mitochondrial ATP-sensitive potassium
(KATPase) channels. These KATPase channels are
also responsible for myocardial ischaemic
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preconditioning, and their inhibition by
sulphonylurea use has been attributed, at least
in part, to the historic poorer prognosis after
myocardial infarction of those with diabetes
[61]. This interaction between sulphonylurea
and GLP-1 is well established, however, is not
accounted for in any of the existing studies with
the exception of CAROLINA, comparing DPP-4
inhibitor to sulphonylurea [51]. The possibility
of other interactions in clinical practice
attenuating the endothelial benefits of GLP-1
is possible, if not probable given the multiple
mechanisms of action on the endothelium of
many cardioprotective drugs used
post-myocardial infarction.
CONCLUSION
Incretin-based therapies have demonstrated
endothelial benefit in people with diabetes. To
date, these have failed to translate into
cardiovascular benefit in outcome trials.
Potentially this may be due to the short
duration of trials, the complex multi-morbid
patients participating in these trails, a failure to
tackle diabetes prior to an epigenetic bad
glycemic legacy, or potential interactions with
concomitant medications. This not
withstanding, the profile of incretin-based
drugs providing good glycemic control, with
low risk of hypoglycemia and weight neutrality
or benefit render them a suitable option after
metformin, compared to alternatives associated
with higher rates of hypoglycemia and weight
gain, both of which have been demonstrated to
adversely impact cardiovascular outcomes.
Future work, exploring cardiovascular
outcomes over longer time frames, such as the
LEADER trial, earlier in diabetes such as VERIFY,
or in the absence of potential interacting
therapies such as CAROLINA may demonstrate
benefits and help elucidate the ideal candidate
for incretin-based intervention.
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